Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore
ChemMedChem · 2024
DOI: 10.1002/cmdc.202400040 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Kotaro Ochiai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-0062, Japan. Hauptthemen laut MEDLINE: Androgen Receptor Antagonists, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Grants in-Aid for Scientific Research from JSPS, Takeda Science Foundation, Hoansha Foundation.
Abstract (Originalsprache)
We previously identified nitrophenylferrocenes and cyanophenylferrocenes as promising lead structures of novel androgen receptor (AR) antagonists, based on the structural similarity between ferrocene and the steroidal skeleton. In the present research, we explored the structure‐activity relationship (SAR) of phenylferrocene derivatives. Introduction of a hydrophobic substituent such as a chlorine atom at the 2‐position or 3‐position of phenylferrocene derivatives significantly increased the antagonistic activity toward wild‐type AR, and among the synthesized compounds, 3‐chloro‐4‐cyanophenylferrocene ( 29 ) exhibited the most potent anti‐proliferative activity toward the androgen‐dependent growth of SC‐3 cells expressing wild‐type AR (IC 50 14 nM). Like conventional antiandrogens such as hydroxyflutamide, the major active metabolite of flutamide, compound 29 exhibited agonistic activity toward T877A‐AR, a mutant AR expressed in human prostate cancer cell line LNCaP. Notably, however, the 2‐chloro isomer 27 showed potent antagonistic activity toward wild‐type AR (IC 50 49 nM) and also exhibited antagonistic activity toward T877A‐AR. Our SAR data should prove helpful for the development of new‐generation AR antagonists based on phenylferrocene as candidate agents to treat drug‐resistant prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-0062, Japan.
ORCID-Profile: Shinya Fujii
Förderung
- Grants in-Aid for Scientific Research from JSPS
- Takeda Science Foundation
- Hoansha Foundation
- Research Center for Biomedical Engineering
- Grant-in-Aid for JSPS Fellows
- AMED
- Japan Agency for Medical Research and Development
Zitieren
APA
Ochiai, K., Yonezawa, R., & Fujii, S. (2024). Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore. ChemMedChem. https://doi.org/10.1002/cmdc.202400040
Vancouver
Ochiai K, Yonezawa R, Fujii S. Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore. ChemMedChem. 2024. doi:10.1002/cmdc.202400040
BibTeX
@article{Ochiai2024,
author = {Ochiai, Kotaro and Yonezawa, Ryo and Fujii, Shinya},
title = {Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202400040}
}
EUVIMED